1. NCCN Clinical Practice Guidelines in Oncology. Cancer-associated Venous Thromboembolic disease. Version
2. 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Accessed by 06.12.2014
3. Khorana AA, Kuderer N, Culakova E, et al. Development and validation of a predictive model for chemotherapyassociated thrombosis. Blood 2008;111: 4902-7.
4. Gary T, Belaj K, Steidl K, et al. Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. Br J Cancer 2012;107:1244-8.
5. Palumbo JS, Talmage KE, Massari JV et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007;110:133-141.
6. Monreal M, Falga C, Valdes M et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006;4: 1950-6.
7. Khorana AA, Connolly GC. Assessing Risk of Venous Thromboembolism in the Patient With Cancer. J Clin Oncol 2009;27:4839-47.
8. Konigsbrugge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thrombosis Research 2014;133:39-43.
9. Roach REJ, Lijfering WM, van Hylckama VA et al. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood 2013;122: 4264-9.
10. Riedl J, Kaider A, Reitter E-M et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer: results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost 2013;111:670-8.
11. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomized controlled trials. Thromb Haemost 2012;108:1042-8.
12. Short N, Connors J. New Oral Anticoagulants and the Cancer Patient. The Oncologist 2014; 19: 82-93.
13. Spinler SA. New Concepts in Heparin-Induced Thrombocytopenia: Diagnosis and Management. J Thromb Thrombolysis 2006;21(1):17-21.
14. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012;10(5):807-14
15. Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT). Available at: http://clinicaltrials.gov/ct2/show/NCT02048865. Accessed by 06.12.2014
16. Gerotziafas GT, Mahe I, Elalamy I. New orally active anticoagulants agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag 2014;10: 423-36.
